In the ICS-positive PMTSs (Figures 1E-H), the differences included more frequent solid-trabecular dominant growth pattern and subtype (p = 0.011 and 0.022, respectively), higher frequency of oncocytic metastatic tumors (p = 0.038) and of p16-positivity (in > 75% TECs, p = 0.007). The gene discussed is CDKN2A; the disease is metastatic neoplasm.